Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?

Table 1 Main clinical and laboratory parameters of enrolled patients

	Patients with MC	Patients without MC	P value
Watery diarrhea	17/25 (68%)	10/23 (43%)	0.08
Abdominal pain	16/25 (64%)	10/23 (43%)	0.15
Weight loss	11/25 (44%)	3/23 (13%)	0.01
Nausea/vomiting	7/25 (28%)	4/23 (17%)	0.29
Epigastric pain	6/25 (24%)	5/23 (21%)	0.85
Asthenia	5/25 (20%)	4/23 (17%)	0.55
Bloating	4/25 (16%)	5/23 (21%)	0.44
GERD	2/25 (8%)	4/23 (17%)	0.33
Constipation	0/25 (0%)	4/23 (17%)	0.04
History of allergy	10/25 (40%)	10/23 (43%)	0.40
PPIs use	4/25 (16%)	6/23 (26%)	0.44
NSAIDs use	1/25 (4%)	0/23 (0%)	0.34
ANA positivity	4/25 (16%)	8/23 (34%)	0.46
ESR increased	2/25 (8%)	6/23 (26%)	0.13
CRP increased	2/25 (8%)	5/23 (21%)	0.21
Helicobacterpylori infection	6/25 (24%)	8/23 (34%)	0.61

MC: Microscopic colitis; GERD: Gastroesophageal reflux disease; PPIs: Proton pump inhibitors; NSAIDs: Nonsteroidal anti-inflammatory drugs; ANA: Anti-nuclear antibody; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein.